These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36316040)

  • 1. Novel
    Deland L; Keane S; Bontell TO; Fagman H; Sjögren H; Lind AE; Carén H; Tisell M; Nilsson JA; Ejeskär K; Sabel M; Abel F
    Cancer Genomics Proteomics; 2022; 19(6):711-726. PubMed ID: 36316040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a Novel MAN1A1-ROS1 Fusion Gene Through mRNA-based Screening for Tyrosine Kinase Gene Aberrations in a Patient with Leiomyosarcoma.
    Suehara Y; Kohsaka S; Hayashi T; Akaike K; Kurisaki-Arakawa A; Sato S; Kobayashi E; Mizuno S; Ueno T; Morii T; Okuma T; Kurihara T; Hasegawa N; Sano K; Sasa K; Okubo T; Kim Y; Mano H; Saito T
    Clin Orthop Relat Res; 2021 Apr; 479(4):838-852. PubMed ID: 33196586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GOPC-ROS1 Fusion Due to Microdeletion at 6q22 Is an Oncogenic Driver in a Subset of Pediatric Gliomas and Glioneuronal Tumors.
    Richardson TE; Tang K; Vasudevaraja V; Serrano J; William CM; Mirchia K; Pierson CR; Leonard JR; AbdelBaki MS; Schieffer KM; Cottrell CE; Tovar-Spinoza Z; Comito MA; Boué DR; Jour G; Snuderl M
    J Neuropathol Exp Neurol; 2019 Dec; 78(12):1089-1099. PubMed ID: 31626289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a novel KLC1-ROS1 fusion in a case of pediatric low-grade localized glioma.
    Nakano Y; Tomiyama A; Kohno T; Yoshida A; Yamasaki K; Ozawa T; Fukuoka K; Fukushima H; Inoue T; Hara J; Sakamoto H; Ichimura K
    Brain Tumor Pathol; 2019 Jan; 36(1):14-19. PubMed ID: 30350109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tyrosine kinase receptor gene fusion: A series of four cases of infantile-type hemispheric glioma].
    Sourty B; Basset L; Michalak S; Colin E; Zidane-Marinnes M; Delion M; de Carli E; Rousseau A
    Ann Pathol; 2023 Nov; 43(6):462-474. PubMed ID: 37635016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.
    Neel DS; Allegakoen DV; Olivas V; Mayekar MK; Hemmati G; Chatterjee N; Blakely CM; McCoach CE; Rotow JK; Le A; Karachaliou N; Rosell R; Riess JW; Nichols R; Doebele RC; Bivona TG
    Cancer Res; 2019 Feb; 79(3):546-556. PubMed ID: 30538120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by
    Sato H; Schoenfeld AJ; Siau E; Lu YC; Tai H; Suzawa K; Kubota D; Lui AJW; Qeriqi B; Mattar M; Offin M; Sakaguchi M; Toyooka S; Drilon A; Rosen NX; Kris MG; Solit D; De Stanchina E; Davare MA; Riely GJ; Ladanyi M; Somwar R
    Clin Cancer Res; 2020 Jun; 26(12):2932-2945. PubMed ID: 32122926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.
    Davare MA; Henderson JJ; Agarwal A; Wagner JP; Iyer SR; Shah N; Woltjer R; Somwar R; Gilheeney SW; DeCarvalo A; Mikkelson T; Van Meir EG; Ladanyi M; Druker BJ
    Clin Cancer Res; 2018 Dec; 24(24):6471-6482. PubMed ID: 30171048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ROS1 Alterations as a Potential Driver of Gliomas in Infant, Pediatric, and Adult Patients.
    Meredith DM; Cooley LD; Dubuc A; Morrissette J; Sussman RT; Nasrallah MP; Rathbun P; Yap KL; Wadhwani N; Bao L; Wolff DJ; Ida C; Sukhanova M; Horbinski C; Jennings LJ; Farooqi M; Gener M; Ginn K; Kam KL; Sasaki K; Kanagal-Shamanna R; Alexandrescu S; Brat D; Lu X
    Mod Pathol; 2023 Nov; 36(11):100294. PubMed ID: 37532182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and functional characterization of the oncogenicity and targetability of a novel
    Jain P; Iyer S; Straka J; Surrey LF; Pogoriler J; Han H; Smith T; Busch C; Fox E; Li M; Waanders AJ; Resnick A; Davare MA
    Cold Spring Harb Mol Case Stud; 2022 Oct; 8(6):. PubMed ID: 36307212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.
    Xu S; Wang W; Xu C; Li X; Ye J; Zhu Y; Ge T
    BMC Cancer; 2019 Aug; 19(1):769. PubMed ID: 31382924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KLC1-ROS1 Fusion Exerts Oncogenic Properties of Glioma Cells via Specific Activation of JAK-STAT Pathway.
    Fujii T; Nakano Y; Hagita D; Onishi N; Endo A; Nakagawa M; Yoshiura T; Otsuka Y; Takeuchi S; Suzuki M; Shimizu Y; Toyooka T; Matsushita Y; Hibiya Y; Tomura S; Kondo A; Wada K; Ichimura K; Tomiyama A
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
    Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
    Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
    Aisner DL; Nguyen TT; Paskulin DD; Le AT; Haney J; Schulte N; Chionh F; Hardingham J; Mariadason J; Tebbutt N; Doebele RC; Weickhardt AJ; Varella-Garcia M
    Mol Cancer Res; 2014 Jan; 12(1):111-8. PubMed ID: 24296758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent chromosomal rearrangements of
    Bayard Q; Caruso S; Couchy G; Rebouissou S; Bioulac Sage P; Balabaud C; Paradis V; Sturm N; de Muret A; Guettier C; Bonsang B; Copie C; Letouzé E; Calderaro J; Imbeaud S; Nault JC; Zucman-Rossi J
    Gut; 2020 Sep; 69(9):1667-1676. PubMed ID: 31907296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CEP72-ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next-generation sequencing.
    Zhu YC; Zhou YF; Wang WX; Xu CW; Zhuang W; Du KQ; Chen G
    Thorac Cancer; 2018 May; 9(5):652-655. PubMed ID: 29517860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling.
    Ou SH; Chalmers ZR; Azada MC; Ross JS; Stephens PJ; Ali SM; Miller VA
    Lung Cancer; 2015 Jun; 88(3):352-4. PubMed ID: 25851827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of GOPC-ROS1 (FIG-ROS1) rearrangement in adult human gliomas.
    Karayan-Tapon L; Cortes U; Rivet P; Jermidi C; Vassal G; Wager M; Taillandier L
    Eur J Cancer; 2014 Sep; 50(13):2364-6. PubMed ID: 24999209
    [No Abstract]   [Full Text] [Related]  

  • 19. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
    Roskoski R
    Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel targets in non-small cell lung cancer: ROS1 and RET fusions.
    Gainor JF; Shaw AT
    Oncologist; 2013; 18(7):865-75. PubMed ID: 23814043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.